Endocrine disorders; rheumatic disorders; collagen diseases; dermatologic diseases; allergic states; allergic and inflammatory ophthalmic processes; respiratory diseases; hematologic disorders; neoplastic diseases; edematous states (because of nephrotic syndrome); GI diseases; multiple sclerosis; tuberculous meningitis; trichinosis with neurologic or myocardial involvement.
COPD; Duchenne muscular dystrophy; Graves ophthalmopathy.
Adults: PO 5 to 60 mg/day.
Adults: PO 30 to 60 mg/day for 1 to 2 wk, then taper.
Duchenne Muscular Dystrophy
Adults: PO 0.75 to 1.5 mg/kg/day.
Adults: PO 60 mg/day; taper to 20 mg/day.
Intermediate-acting glucocorticoid that depresses formation, release, and activity of endogenous mediators of inflammation, including prostaglandins, kinins, histamine, liposomal enzymes, and complement system. Also modifies body’s immune response.
Systemic fungal infections; administration of live virus vaccines.
CV: Thromboembolism or fat embolism; thrombophlebitis; necrotizing angiitis; cardiac arrhythmias or ECG changes; syncopal episodes; hypertension; myocardial rupture; CHF.
CNS: Convulsions; pseudotumor cerebri (increased intracranial pressure with papilledema); vertigo; headache; neuritis/paresthesias; psychosis.
DERM: Impaired wound healing; thin fragile skin; petechiae and ecchymoses; erythema; lupus erythematosus-like lesions; subcutaneous fat atrophy; purpura; striae; hirsutism; acneiform eruptions; allergic dermatitis; urticaria; angioneurotic edema; perineal irritation.
EENT: Posterior subcapsular cataracts; increased IOP; glaucoma; exophthalmos.
GI: Pancreatitis; abdominal distention; ulcerative esophagitis; nausea; vomiting; increased appetite and weight gain; peptic ulcer with perforation and hemorrhage; small and large bowel perforation.
GU: Increased or decreased motility and number of spermatozoa.
METAB: Sodium and fluid retention; hypokalemia; hypokalemic alkalosis; metabolic alkalosis; hypocalcemia.
OTHER: Musculoskeletal effects (muscle weakness, steroid myopathy, muscle mass loss, tendon rupture, osteoporosis, aseptic necrosis of femoral and humeral heads, spontaneous fractures, including vertebral compression fractures and pathologic fracture of long bones); endocrine abnormalities (menstrual irregularities, cushingoid state, growth suppression in children secondary to adrenocortical and pituitary unresponsiveness, increased sweating, decreased carbohydrate tolerance, hyperglycemia, glycosuria, increased insulin or sulfonylurea requirements in diabetics, negative nitrogen balance because of protein catabolism, hirsutism); anaphylactoid/hypersensitivity reactions; aggravation or masking of infections; malaise; fatigue; insomnia.
Antagonizes anticholinesterase effects in myasthenia gravis.
Alters anticoagulant dose requirements.
Barbiturates, hydantoins (eg, phenytoin), rifampin
Decreased pharmacologic effect of prednisone.
Enhanced cyclosporine toxicity.
Estrogens, ketoconazole, oral contraceptives
Decreased Cl of prednisone.
Nondepolarizing muscle relaxants
May potentiate, counteract, or have no effect on neuromuscular blocking action.
Reduced serum levels and efficacy of salicylates.
Inhibition of growth-promoting effects of somatrem.
Alterations in pharmacologic activity of either agent.
Therapeutic Classification: corticosteroids (intermediate acting) , immune modifiers
Absorption: Well absorbed after oral administration.
Distribution: Widely distributed; crosses the placenta and probably enters breast milk.
Metabolism/Excretion: Converted by the liver to prednisolone, which is then metabolized by the liver.
Half-life: 3.4–3.8 hr (plasma), 18–36 hr (tissue); adrenal suppression lasts 1.25–1.5 days.
Copyright ©Nims Drugs2015. All rights reserved.
Powered by : web creation Nepal